TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02865850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
Study: NCT05178095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial intelligence
Description: Colonoscopy with the aid of artificial intelligence for the detection of colonic polyps

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: No Artificial Intelligence
Description: Colonoscopy without the aid of artificial intelligence for the detection of colonic polyps
Study: NCT02722044

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M923
Description: Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autoinjector
Description: Subcutaneous administration
Study: NCT03947229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel mono-therapy
Description: Patients will receive clopidogrel (75 mg once daily) monotherapy without co-administration of aspirin for 24 months after randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual-antiplatelet therapy
Description: Patients will receive co-administration of aspirin (100 mg/day) and clopidogrel (75 mg/day) for 24 months after randomization.
Study: NCT02863198

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endometrial injury
Description: Endometrial injury was done only for patient of the study group. It was done on day 5, under complete aseptic conditions, no anesthesia, was given in most of cases. Endometrial local injury was performed on the posterior wall, midline, and 10-15 mm from the fundus using pipelle endometrial sampling (Pipelle).
Study: NCT01483677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nintendo Wii
Description: Subjects played the game Boomblox for 30 continuous minutes on the Nintendo Wii.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Playstation 2
Description: Subjects played the game Time Crisis2 on the Playstation2 for 30 continuous minutes.
Study: NCT03058744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-118 Lotion
Description: Lotion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP Monad Lotion
Description: Lotion
Study: NCT00266474

Intervention type: OTHER
Intervention: Assessment of upper and lower airway colonization, sinonasal symptoms, history, rhinoscopy and rhinomanometry.
Study: NCT03058744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultravate Cream
Description: Cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazorac Cream
Description: Cream
Study: NCT02942264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zotiraciclib (TG02)
Description: Phase I: Two treatment arms and several dose levels are planned; In the maximum tolerated dose (MTD) finding part, Temozolomide (TMZ) with two alternate schedules (dose dense (dd) and metronomic (mn) in combination with Zotiraciclib (TG02) will be administered;~--A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: (winner of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design. The dosage for the combination arm will be derived from the MTD determined in the Phase I component of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zotiraciclib (TG02)
Description: Phase I: Two treatment arms and several dose levels are planned; In the maximum tolerated dose (MTD) finding part, Temozolomide (TMZ) with two alternate schedules (dose dense (dd) and metronomic (mn) in combination with Zotiraciclib (TG02) will be administered;~--A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: (winner of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design. The dosage for the combination arm will be derived from the MTD determined in the Phase I component of the study.
Study: NCT01832415

Intervention type: DRUG
Intervention: Bevacizumab
Description: Observation of bevacizumab administration in first line ovarian cancer treatment
Study: NCT02942264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zotiraciclib (TG02)
Description: Phase I: Two treatment arms and several dose levels are planned; In the maximum tolerated dose (MTD) finding part, Temozolomide (TMZ) with two alternate schedules (dose dense (dd) and metronomic (mn) in combination with Zotiraciclib (TG02) will be administered;~--A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: (winner of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design. The dosage for the combination arm will be derived from the MTD determined in the Phase I component of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: Phase I: In the maximum tolerated dose (MTD) finding part, Temozolomide (TMZ) with two alternate schedules (dose dense (dd) and metronomic (mn) in combination with Zotiraciclib (TG02) will be administered; A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: (winner of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design.
Study: NCT02406261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: 50 mg lanabecestat will be administered orally as 1 × 50-mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 20 mg simvastatin will be administered orally as 1 × 20-mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 500 mcg midazolam will be administered orally as 0.25 mL of 2-mg/mL syrup
Study: NCT02942264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: Phase I: In the maximum tolerated dose (MTD) finding part, Temozolomide (TMZ) with two alternate schedules (dose dense (dd) and metronomic (mn) in combination with Zotiraciclib (TG02) will be administered; A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: (winner of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: Phase I: In the maximum tolerated dose (MTD) finding part, Temozolomide (TMZ) with two alternate schedules (dose dense (dd) and metronomic (mn) in combination with Zotiraciclib (TG02) will be administered; A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: (winner of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide (TMZ)
Description: Phase I: In the maximum tolerated dose (MTD) finding part, Temozolomide (TMZ) with two alternate schedules (dose dense (dd) and metronomic (mn) in combination with Zotiraciclib (TG02) will be administered; A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: (winner of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design.
Study: NCT02313688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastrectomy
Description: Transabdominal (include transhiatal) D2 gastrectomy according JGCA gastric cancer treatment guidelines (2010, ver.3) and with 3±0.5 cm lengthen proximal resection margin.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastrectomy
Description: Transabdominal (include transhiatal) D2 gastrectomy according JGCA gastric cancer treatment guidelines (2010, ver.3) and with 5±0.5 cm lengthen proximal resection margin.
Study: NCT04807959

Intervention type: OTHER
Intervention: 20Lighter anti-obesity program
Description: A customized expert supervised 3-phase program including non-invasive proprietary nutritional, behavioral, and physiological components.
Study: NCT00926926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Chloride Gel
Description: Once daily for 7 days, followed by single dose of acetaminophen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Once daily for 7 days, followed by single dose of acetaminophen
Study: NCT01696461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Study: NCT01943656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tobii™ Eyegaze System
Description: Volunteers will be instructed and trained to use the Tobii™ Eyegaze System. The number of sessions required to successfully master the device depends on the learning curve of the patient. The progress will be documented accordingly. After successful completion of the training and supervised use, the inpatients will be offered the Tobii™ Eyegaze System for unsupervised use, 4 hours a week, for the following 2 months.
Study: NCT01714466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NER1006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MOVIPREP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOVIPREP
Study: NCT04166552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients will be randomized to receive EHP-101 or Placebo
Description: EHP-101 or placebo will be taken once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients will be randomized to receive EHP-101 or Placebo
Description: EHP-101 or placebo will be taken once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients will be randomized to receive EHP-101 or Placebo
Description: EHP-101 or placebo will be taken twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients will be randomized to receive EHP-101 or Placebo
Description: EHP-101 or placebo will be taken twice a day
Study: NCT04447547

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T
Description: Biological: CD19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
Study: NCT04143633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Description: The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. The distribution of carbohydrates depends on the content of fodmaps on each food.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Description: The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. The distribution of carbohydrates depends on the content of fodmaps on each food.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low FODMAP diet
Description: The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. The distribution of carbohydrates depends on the content of fodmaps on each food.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard diet
Description: The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. Cruciferous vegetables, fruits and condiments will be eliminated and a normal content of fodmap.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard diet
Description: The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. Cruciferous vegetables, fruits and condiments will be eliminated and a normal content of fodmap.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard diet
Description: The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. Cruciferous vegetables, fruits and condiments will be eliminated and a normal content of fodmap.
Study: NCT00902837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone naloxone prolonged release tablets (OXN)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone prolonged release tablet
Study: NCT02792426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Research ENDS S-TA-U001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Research ENDS S-TA-U001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Research ENDS S-TA-U001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette Inhalator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette Inhalator
Study: NCT00938106

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: optimised magnetic resonance image-guided intra-uterine brachytherapy
Description: Brachytherapy treatment will be planned based on the MRI test and will be individualized for each study participant,based on participant's cancer and body inside.Brachytherapy will be as an inpatient over 2-3 days. All other care will follow standard procedures.
Study: NCT04511507

Intervention type: PROCEDURE
Intervention: hemoadsorption
Description: three consecutive sessions of hemoadsorption in patients with liver failure
Study: NCT03079765

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral skills training
Description: Participants will receive feedback and error correction on their implementation of the assessment procedures. Feedback will take the form of the experimenter pointing out components of the assessment that are not being conducted accurately and error correction will take the form of the experimenter reviewing the correct way to implement that component of the assessment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protocol Only
Description: Participants will be given a written protocol describing how to conduct the target assessment procedure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Protocol Only
Description: Participants will be given a written protocol describing how to conduct the target assessment procedure.
Study: NCT02776878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Study: NCT04383431

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PACK-CXL
Description: Standard epithelium-off CXL, 12 minutes soaking time with riboflavin, 8 minutes UVA corneal irradiation pulsed mode.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PACK-CXL
Description: Standard epithelium-off CXL, 12 minutes soaking time with riboflavin, 8 minutes UVA corneal irradiation pulsed mode.
Study: NCT00902837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone naloxone tablet
Study: NCT01645839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Cytarabine
Description: 50mg (5 mL) by slow intrathecal injection (1-5 minutes) directly into the cerebrospinal fluid (CSF) via a ventricular catheter directly into the lumbar sac during a lumbar puncture.
Study: NCT01328093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY2140023
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Administered orally
Study: NCT03570905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar Tong Splint
Description: A splint made of 8-10 layers of plaster rolled into a single long sheet which begins at the distal volar crease of the hand and traverses around the elbow and stops at the dorsal metacarpal heads. The skin is protected with cotton cast padding (webril) and the splint is held in place with ace bandages
Study: NCT00977652

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: active stimulation
Description: percutaneous posterior tibial nerve stimulation with following parameters: frequency: 14hz; impulse duration: 210usec;intensity:sensibility threshold during 3 months

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: Same location with the same device than active stimulation but amplitude of stimulation = 0
Study: NCT03570905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clam Shell Splint
Description: A 2-part splint made of 8-10 layers of plaster. The piece traverses from the distal volar crease of the hand to the volar aspect of the proximal forearm. The second piece runs along the dorsal aspect of forearm from metacarpal heads to proximal forearm. The elbow is left free. In the same fashion as the sugar tong splint, the skin is protected with cotton cast padding (webril) and held in place with ace wrap
Study: NCT04032340

Intervention type: OTHER
Intervention: dog presence
Description: This project seeks to assess positive impacts of companion dog presence in elderly living at home ; to assess loneliness and isolement between eldlery with a companion dog and without, at home
Study: NCT01322815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy and GI-4000
Description: Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.~maintenance of GI-4000 injection and bevacizumab every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: 40 YU GI-4000 every 2 weeks Bevacizumab every 2 weeks
Study: NCT01113424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Single-dose of a new Nicotine Replacement Therapy (NRT) product 2 mg and 4 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Single-dose of a new Nicotine Replacement Therapy (NRT) product 2 mg and 4 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette® (Nicotine Gum)
Description: Single-dose of marketed nicotine gum 2 mg or 4 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette® (Nicotine Gum)
Description: Single-dose of marketed nicotine gum 2 mg or 4 mg
Study: NCT01336322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 850 mg bid
Study: NCT02297789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigative Full Face Mask with Headgear
Study: NCT01336322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100 mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin + Metformin
Description: sitagliptin 100mg + metformin 850mg
Study: NCT03781557

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid
Description: High-concentrated DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid
Description: High-concentrated EPA

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: Olive Oil softgels
Study: NCT01974791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GET Living
Description: GET Living is an exposure based treatment jointly delivered by a cognitive-behavioral therapist and physical therapy to help children and adolescents suffering with chronic pain and headache progressively return to valued life activities.
Study: NCT01935219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training
Description: 9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Processing Speed Training
Description: 9 weeks, a total of 10 hours of computer-based processing speed training; 60-75 minutes/week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Processing Speed Training
Description: 9 weeks, a total of 10 hours of computer-based processing speed training; 60-75 minutes/week

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brain Health Workshop
Description: 9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Health Workshop
Description: 9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer